622 related articles for article (PubMed ID: 31633853)
21. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
[TBL] [Abstract][Full Text] [Related]
22. A prospective study of hepatitis C incidence in Australian prisoners.
Luciani F; Bretaña NA; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR;
Addiction; 2014 Oct; 109(10):1695-706. PubMed ID: 24916002
[TBL] [Abstract][Full Text] [Related]
23. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.
Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J;
J Viral Hepat; 2017 Sep; 24(9):733-741. PubMed ID: 28256027
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel.
Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C;
Int J Drug Policy; 2021 Dec; 98():103379. PubMed ID: 34311138
[TBL] [Abstract][Full Text] [Related]
25. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
[TBL] [Abstract][Full Text] [Related]
26. Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study.
Stone J; Lim AG; Dore GJ; Borquez A; Geddes L; Gray R; Grebely J; Hajarizadeh B; Iversen J; Maher L; Valerio H; Martin NK; Hickman M; Lloyd AR; Vickerman P
Liver Int; 2023 Mar; 43(3):569-579. PubMed ID: 36305315
[TBL] [Abstract][Full Text] [Related]
27. The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting.
Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C
Addiction; 2021 May; 116(5):1162-1171. PubMed ID: 33006784
[TBL] [Abstract][Full Text] [Related]
28. The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada.
Godin A; Kronfli N; Cox J; Alary M; Maheu-Giroux M
Int J Drug Policy; 2021 Feb; 88():102738. PubMed ID: 32278651
[TBL] [Abstract][Full Text] [Related]
29. Incidence, prevalence and risk factors for hepatitis C in Danish prisons.
Søholm J; Holm DK; Mössner B; Madsen LW; Hansen JF; Weis N; Sauer AP; Awad T; Christensen PB
PLoS One; 2019; 14(7):e0220297. PubMed ID: 31348813
[TBL] [Abstract][Full Text] [Related]
30. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
[TBL] [Abstract][Full Text] [Related]
31. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.
Butler K; Larney S; Day CA; Burns L
Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702
[TBL] [Abstract][Full Text] [Related]
32. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia.
Altice FL; Azbel L; Stone J; Brooks-Pollock E; Smyrnov P; Dvoriak S; Taxman FS; El-Bassel N; Martin NK; Booth R; Stöver H; Dolan K; Vickerman P
Lancet; 2016 Sep; 388(10050):1228-48. PubMed ID: 27427455
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
Kwon JA; Chambers GM; Luciani F; Zhang L; Kinathil S; Kim D; Thein HH; Botha W; Thompson S; Lloyd A; Yap L; Gray RT; Butler T
PLoS One; 2021; 16(2):e0245896. PubMed ID: 33571196
[TBL] [Abstract][Full Text] [Related]
34. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
35. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
36. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
[TBL] [Abstract][Full Text] [Related]
37. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
[TBL] [Abstract][Full Text] [Related]
38. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
[TBL] [Abstract][Full Text] [Related]
39. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
Iversen J; Wand H; McManus H; Dore GJ; Maher L
Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
[TBL] [Abstract][Full Text] [Related]
40. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Addiction; 2018 Mar; 113(3):545-563. PubMed ID: 28891267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
